Imaprelimab, a CD146 antibody approved for clinical testing, was tested for safety, tolerability, pharmacokinetics and immunogenicity in approximately 40 healthy volunteers (ClinicalTrials.gov ID: NCT2458677) and 56 patients with psoriasis (ClinicalTrials.gov ID: NCT02630901). This evidence concerns the gene MCAM and psoriasis.